Stockscreener 앱 받기
6.40
0.00%
0.00
시간 외 거래:
6.40
전일 마감가:
$6.40
열려 있는:
$6.45
하루 거래량:
1.04M
Relative Volume:
0.76
시가총액:
$648.72M
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-3.2821
EPS:
-1.95
순현금흐름:
$-197.47M
1주 성능:
-7.65%
1개월 성능:
+1.27%
6개월 성능:
-47.71%
1년 성능:
-57.28%
1일 변동 폭
$6.375
$6.57
1주일 범위
$6.32
$7.00
52주 변동 폭
$6.08
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.40 | 702.44M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
What analysts say about Day One Biopharmaceuticals Inc. stockExtraordinary performance - Autocar Professional
Is Day One Biopharmaceuticals Inc. a good long term investmentFree Stock Market Query - Autocar Professional
Day One Biopharmaceuticals Inc. Stock Analysis and ForecastLightning-fast growth - jammulinksnews.com
What drives Day One Biopharmaceuticals Inc. stock priceTremendous wealth creation - jammulinksnews.com
How Day One Biopharmaceuticals Inc. stock performs during market volatilityFree Access to Community - Newser
Why Day One Biopharmaceuticals Inc. stock attracts strong analyst attentionTop Performing Low Risk Stocks - Newser
What makes Day One Biopharmaceuticals Inc. stock price move sharplyFree Investment Group - Newser
When the Price of (DAWN) Talks, People Listen - news.stocktradersdaily.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Makes New $88,000 Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Announces Pricing of Upsized Initial Public Offering - IT Business Net
Day One Biopharmaceuticals, Inc. shares rise 4.16% intraday after positive mid-term outlook from Lonza Group. - AInvest
DAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More - Nasdaq
AMPY Stock: A Voyage Through Amplify Energy Corp’s Finances - investchronicle.com
(DAWN) On The My Stocks Page - news.stocktradersdaily.com
When Will Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Breakeven? - Yahoo Finance
TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN) - MSN
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Day 9 of Loss Streak for Day One Biopharmaceuticals Stock with -12% Return (vs. -50% YTD) [6/20/2025] - Trefis
Day 8 of Loss Streak for Day One Biopharmaceuticals Stock with -11% Return (vs. -49% YTD) [6/18/2025] - Trefis
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Brokerages - Defense World
Pallas Capital Advisors LLC Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Bank of America Corp DE Has $260,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Where are the Opportunities in (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Day One Appoints Michael Vasconcelles As Head Of Research And Development - MarketScreener
Day One Biopharmaceuticals (DAWN) Welcomes New R&D Leader | DAWN Stock News - GuruFocus
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development - GlobeNewswire
Day One Taps ImmunoGen Executive to Lead R&D: 25-Year Oncology Expert Joins Cancer Drug Developer - Stock Titan
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT - MSN
Ameriprise Financial Inc. Decreases Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Squarepoint Ops LLC Acquires New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - Insider Monkey
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
Nuveen Asset Management LLC Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLC - Defense World
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):